Alnylam Pharmaceuticals (NASDAQ:ALNY) announced Wednesday that Nasdaq had halted trading of the company's shares amid an FDA AdCom meeting on its amyloidosis drug patisiran.
A group of FDA experts is expected to meet today to discuss the company's marketing application to expand the label of RNAi therapeutic for cardiomyopathy (CM) linked to transthyretin-mediated (ATTR) amyloidosis.
The meeting is scheduled to start at 9:00 a.m. ET and will conclude after a vote on whether the benefits of patisiran outweigh its risks for the indication.